Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.53 |
| ▸ | IL1RN | P18510 | 1/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482661 | 0.86 | CA1 (0.53) | KMT2AMEN1ALDH1A1CA2CA12 | |
| SCHEMBL4605372 | 0.78 | KEAP1 (0.46) | KEAP1IL1RNERAP1KMT2AMEN1 | |
| SCHEMBL6690757 | 0.77 | AURKA (0.47) | KMT2AMEN1ALDH1A1POLBMAPT | |
| SCHEMBL157674 | 0.76 | L3MBTL1 (0.40) | ALDH1A1CA2CA12CA9CA1 | |
| SCHEMBL1827999 | 0.76 | CA1 (0.30) | CA2CA1 | |
| SCHEMBL11427391 | 0.75 | ALDH1A1 (0.51) | KEAP1KMT2AMEN1PKMALDH1A1 | |
| SCHEMBL5510889 | 0.73 | KEAP1 (0.48) | KEAP1IL1RNERAP1KMT2AMEN1 | |
| SCHEMBL9059802 | 0.73 | L3MBTL1 (0.42) | KMT2APOLB | |
| SCHEMBL7447109 | 0.73 | CA2 (0.55) | CA2CA12CA9CA1 | |
| SCHEMBL150811 | 0.72 | HTR6 (0.38) | KMT2AMEN1CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301464-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2003-04-16 | — | — | EP | claimed |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-14 | — | — | US | claimed |
| WO-2002004403-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-01-17 | — | — | WO | claimed |
| US-4140684-A | FOR POLYESTERS, POLYAMIDES, AND CELLULOSE ACETATES | FIDELITY UNION TRUST COMPANY, EXECUTIVE TRUSTEE UNDER THE SANDOZ TRUST (US) | 1979-02-20 | — | — | US | claimed |
| US-10265279-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | ORYZON GENOMICS, S.A. (ES) | 2019-04-23 | — | — | US | disclosed |
| US-20170281567-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | HOFFMANN-LA ROCHE INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-1301464-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2003-04-16 | — | — | EP | disclosed |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-14 | — | — | US | disclosed |
| WO-2002004403-A1 | BIPHENYLCARBOXYLIC ACID AMIDES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-01-17 | — | — | WO | disclosed |
| US-4229343-A | Azo dyes from an oxadiazolyl-substituted aniline | BASF AKTIENGESELLSCHAFT (DE) | 1980-10-21 | — | — | US | disclosed |
| US-4202814-A | AZO DYES GIVING FAST RED COLOR | CIBA-GEIGY CORPORATION (US) | 1980-05-13 | — | — | US | disclosed |
| US-4198205-A | SULFONIC ACID-FREE DISPERSE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | disclosed |
| US-4179435-A | SULPHONIC ACID-FREE | CIBA-GEIGY CORPORATION (US) | 1979-12-18 | — | — | US | disclosed |
| US-4140684-A | FOR POLYESTERS, POLYAMIDES, AND CELLULOSE ACETATES | FIDELITY UNION TRUST COMPANY, EXECUTIVE TRUSTEE UNDER THE SANDOZ TRUST (US) | 1979-02-20 | — | — | US | disclosed |
| US-4115381-A | FOR POLYESTER FIBERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-4016151-A | Phenyl-substituted phthalazone azo dyes with a coupling component of the phenol, napthol, acetoacetarylide, pyrazolone, quinolone, pyridine, pyrimidone or isoquinolone series | BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265279-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | KDM1B, DOT1L, KDM1A | KEAP1 236/4885IL1RN 2214/4885ERAP1 2585/4885 |
| US-20020032238-A1 | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments | MTTP, CETP, FABP1 | KEAP1 906/4885IL1RN 676/4885ERAP1 438/4885 |
| US-20170281567-A1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS | KDM1B, DOT1L, KDM1A | KEAP1 236/4885IL1RN 2214/4885ERAP1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.